This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Feng S, De Carvalho DD. Clinical advances in targeting epigenetics for cancer therapy. FEBS J. 2022 Mar;289(5):1214–1239. doi: 10.1111/febs.15750. Epub 2021 Feb 18. PMID: 33545740.FengSDe CarvalhoDDClinical advances in targeting epigenetics for cancer therapyFEBS J.2022Mar28951214123910.1111/febs.15750Epub 2021 Feb 18. PMID: 33545740.33545740Open DOISearch in Google Scholar
Liu Z, Ren Y, Weng S, Xu H, Li L, Han X. A New trend in cancer treatment: the combination of epigenetics and immunotherapy. Front Immunol. 2022 Jan 24;13:809761. doi: 10.3389/fimmu.2022.809761. PMID: 35140720; PMCID: PMC8818678.LiuZRenYWengSXuHLiLHanXA New trend in cancer treatment: the combination of epigenetics and immunotherapyFront Immunol.2022Jan2413809761.10.3389/fimmu.2022.809761PMID: 35140720; PMCID: PMC8818678.881867835140720Open DOISearch in Google Scholar
Schübeler D. Function and information content of DNA methylation. Nature. 2015 Jan 15;517(7534):321–6. doi: 10.1038/nature14192. PMID: 25592537.SchübelerDFunction and information content of DNA methylationNature.2015Jan155177534321610.1038/nature14192PMID: 25592537.25592537Open DOISearch in Google Scholar
Magner WJ, Kazim AL, Stewart C, Romano MA, Catalano G, Grande C, et al. Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors. J Immunol. 2000 Dec 15;165(12):7017–24. doi: 10.4049/jimmunol.165.12.7017. PMID: 11120829.MagnerWJKazimALStewartCRomanoMACatalanoGGrandeCActivation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitorsJ Immunol.2000Dec151651270172410.4049/jimmunol.165.12.7017PMID: 11120829.11120829Open DOISearch in Google Scholar
Roulois D, Loo Yau H, Singhania R, Wang Y, Danesh A, Shen SY, et al. DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell. 2015 Aug 27;162(5):961–73. doi: 10.1016/j.cell.2015.07.056. PMID: 26317465; PMCID: PMC4843502.RouloisDLoo YauHSinghaniaRWangYDaneshAShenSYDNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcriptsCell.2015Aug2716259617310.1016/j.cell.2015.07.056PMID: 26317465; PMCID: PMC4843502.484350226317465Open DOISearch in Google Scholar
Heiland DH, Haaker G, Delev D, Mercas B, Masalha W, Heynckes S, et al. Comprehensive analysis of PD-L1 expression in glioblastoma multiforme. Oncotarget. 2017 Jun 27;8(26):42214–42225. doi: 10.18632/oncotarget.15031. PMID: 28178682; PMCID: PMC5522061.HeilandDHHaakerGDelevDMercasBMasalhaWHeynckesSComprehensive analysis of PD-L1 expression in glioblastoma multiformeOncotarget.2017Jun27826422144222510.18632/oncotarget.15031PMID: 28178682; PMCID: PMC5522061.552206128178682Open DOISearch in Google Scholar
Gevensleben H, Holmes EE, Goltz D, Dietrich J, Sailer V, Ellinger J, et al. PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy. Oncotarget. 2016 Nov 29;7(48):79943–79955. doi: 10.18632/oncotarget.13161. PMID: 27835597; PMCID: PMC5346762.GevenslebenHHolmesEEGoltzDDietrichJSailerVEllingerJPD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomyOncotarget.2016Nov29748799437995510.18632/oncotarget.13161PMID: 27835597; PMCID: PMC5346762.534676227835597Open DOISearch in Google Scholar
Karamitrousis EI, Balgkouranidou I, Xenidis N, Amarantidis K, Biziota E, Koukaki T, et al. Prognostic role of RASSF1A, SOX17 and Wif-1 promoter methylation status in cell-free DNA of advanced gastric cancer patients. Technol Cancer Res Treat. 2021 Jan–Dec;20:1533033820973279. doi: 10.1177/1533033820973279. PMID: 33928818; PMCID: PMC8113658.KaramitrousisEIBalgkouranidouIXenidisNAmarantidisKBiziotaEKoukakiTPrognostic role of RASSF1A, SOX17 and Wif-1 promoter methylation status in cell-free DNA of advanced gastric cancer patientsTechnol Cancer Res Treat.2021Jan–Dec201533033820973279.10.1177/1533033820973279PMID: 33928818; PMCID: PMC8113658.811365833928818Open DOISearch in Google Scholar
Karamitrousis E, Balgkouranidou I, Xenidis N, Amarantidis K, Biziota E, Koukaki T, et al. Association between SOX17, Wif-1 and RASSF1A promoter methylation status and response to chemotherapy in patients with metastatic gastric cancer. Clin Chem Lab Med. 2020 Sep 1;59(2):e73–e75. doi: 10.1515/cclm-2020-0662. PMID: 32870805.KaramitrousisEBalgkouranidouIXenidisNAmarantidisKBiziotaEKoukakiTAssociation between SOX17, Wif-1 and RASSF1A promoter methylation status and response to chemotherapy in patients with metastatic gastric cancerClin Chem Lab Med.2020Sep1592e73e7510.1515/cclm-2020-0662PMID: 32870805.32870805Open DOISearch in Google Scholar
Wang L, Amoozgar Z, Huang J, Saleh MH, Xing D, Orsulic S, et al. Decitabine Enhances Lymphocyte Migration and Function and Synergizes with CTLA-4 Blockade in a Murine Ovarian Cancer Model. Cancer Immunol Res. 2015 Sep;3(9):1030–41. doi: 10.1158/2326-6066.CIR-15-0073. Epub 2015 Jun 8. PMID: 26056145.WangLAmoozgarZHuangJSalehMHXingDOrsulicSDecitabine Enhances Lymphocyte Migration and Function and Synergizes with CTLA-4 Blockade in a Murine Ovarian Cancer ModelCancer Immunol Res.2015Sep3910304110.1158/2326-6066.CIR-15-0073Epub 2015 Jun 8. PMID: 26056145.Open DOISearch in Google Scholar
Chiappinelli KB, Strissel PL, Desrichard A, Li H, Henke C, Akman B, et al. Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. Cell. 2015 Aug 27;162(5):974–86. doi: 10.1016/j.cell.2015.07.011. Erratum in: Cell. 2016 Feb 25;164(5):1073. Buhu, Sadna [corrected to Budhu, Sadna]; Mergoub, Taha [corrected to Merghoub, Taha]. Erratum in: Cell. 2017 Apr 6;169(2):361. PMID: 26317466; PMCID: PMC4556003.ChiappinelliKBStrisselPLDesrichardALiHHenkeCAkmanBInhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous RetrovirusesCell.2015Aug2716259748610.1016/j.cell.2015.07.011Erratum in: Cell. 2016 Feb 25;164(5):1073. Buhu, Sadna [corrected to Budhu, Sadna]; Mergoub, Taha [corrected to Merghoub, Taha]. Erratum in: Cell. 2017 Apr 6;169(2):361. PMID: 26317466; PMCID: PMC4556003.455600326317466Open DOISearch in Google Scholar
Leslie M. First EZH2 Inhibitor Approved-for Rare Sarcoma. Cancer Discov. 2020 Mar;10(3):333–334. doi: 10.1158/2159-8290.CD-NB2020-006. Epub 2020 Feb 10. PMID: 32041739.LeslieMFirst EZH2 Inhibitor Approved-for Rare SarcomaCancer Discov.2020Mar10333333410.1158/2159-8290.CD-NB2020-006Epub 2020 Feb 10. PMID: 32041739.32041739Open DOISearch in Google Scholar
Karamitrousis E, Balgkouranidou I, Xenidis N, Amarantidis K, Biziota E, Koukaki T, et al. Concentration of circulating tumor DNA in patients with metastatic gastric cancer and its prognostic significance. Forum Clin Oncol. 2021; 12(2): 72–76.KaramitrousisEBalgkouranidouIXenidisNAmarantidisKBiziotaEKoukakiTConcentration of circulating tumor DNA in patients with metastatic gastric cancer and its prognostic significanceForum Clin Oncol.2021122727610.2478/fco-2021-0010Search in Google Scholar
Goni M, Javaregowda PK, Chachadi V, Virupakshaiah DBM. Sialic acids: An avenue to target cancer progression, mestastasis and resistance to therapy. Forum Clin Oncol. 2021;12(2):GoniMJavaregowdaPKChachadiVVirupakshaiahDBMSialic acids: An avenue to target cancer progression, mestastasis and resistance to therapyForum Clin Oncol.202112210.2478/fco-2021-0006Search in Google Scholar
Sharma H, Kumar G, Kaur CD. Development of bioflavonoid containing chemotherapeutic delivery systems for UV damaged skin and kangri cancer. Forum Clin Oncol. 2021;12 (2): 86–98.SharmaHKumarGKaurCDDevelopment of bioflavonoid containing chemotherapeutic delivery systems for UV damaged skin and kangri cancerForum Clin Oncol.2021122869810.2478/fco-2021-0012Search in Google Scholar